Scancell Hldgs Plc
Research Scancell Hldgs Plc (SCLP) on Bullrun: market cap GBX 10.50B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSCLP
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyGBX
- Market capGBX 10.50B
- Financial periodFY2025
- RevenueGBP 4.71M
- Net income-GBP 12.27M
- Free cash flow-GBP 7.94M
- Gross margin94.9%
Valuation Snapshot
latest market cap is GBX 10.50B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 4.71M | -GBP 12.27M | -GBP 7.94M | 94.9% | -0.01 | GBP 16.89M | GBP 16.27M | -GBP 3.84M |
| FY2024 | GBP 0 | -GBP 5.86M | -GBP 15.84M | n/a | -0.01 | GBP 14.82M | GBP 19.87M | -GBP 3.51M |
| FY2023 | GBP 5.27M | -GBP 11.94M | -GBP 8.34M | 90.0% | -0.02 | GBP 19.92M | GBP 19.53M | -GBP 9.65M |
| FY2022 | GBP 0 | -GBP 4.57M | -GBP 11.46M | n/a | 0 | GBP 28.73M | GBP 19.03M | GBP 1.39M |
| FY2021 | GBP 0 | -GBP 15.48M | -GBP 8.55M | n/a | -0.02 | GBP 41.11M | GBP 15.39M | GBP 8.69M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | GBX 10.50B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 GBX.
About Scancell Hldgs Plc
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Scancell Hldgs Plc's market cap?
Scancell Hldgs Plc's market capitalization is GBX 10.50B.
What does Scancell Hldgs Plc do?
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer.